Oct 29th Day 1
Opening Plenary Session
Paradigm shift in vaccine funding capacity and collaborations for disease X and persistent epidemics
What will 2020 hold for immuno-oncology? A global landscape and overview of promising approaches
Morning Networking Break
2 x Interactive Roundtables
Are PD-1 Antibodies transforming cancer therapy?
Biodefence: The role of vaccines in preventing outbreaks, through natural causes or biothreats
Challenges in trial design, implementation and safety assessment under clinical development
Challenges of universal influenza vaccines evaluation
Development pathways for combining immune-based therapies in cancer: leveraging disease biology, complex biomarkers, regulatory approval and pathways to adoption
Do we understand the biology behind cold and hot tumours, which is needed for successful treatment and what is the role for biomarkers?
Establishing a One Health approach to combat emerging zoonotic & transboundary diseases
Further follow up on: Are we pandemic ready for influenza? How to close the gaps in our current strategy in preparedness
Further follow up on: Paradigm shift in vaccine funding capacity and collaborations for disease X and persistent epidemics
Intradermal delivery of therapeutic vaccines – benefits and challenges
Practical use of systems biology in vaccinology
Strategies for selecting the right immuno-oncology tumour model
Strengthening human & animal public health systems at their interface to prevent AMR: Spanish National Action Plan against Antimicrobial Resistance
Unique Operational Challenges for Vaccines Clinical Development.
Virtual trials—do they have a role in vaccine studies
Networking Lunch & Poster Sessions
New Platform & Delivery Technologies
Vector Borne Diseases
What are the AMR targets for vaccines?
Chair’s opening remarks
Harmonising priorities in Europe: Role of public health, government strategies and industry to halting the AMR crisis – do we have a consistent message?
A single-dose live-attenuated Zika vaccine
Afternoon Networking Break
Building international capacity to tackle AMR more efficiently – is this in line with Europe?
Chair closing remarks of day one followed by Drinks Reception host by Enesi Pharma